John Light

“We believe the entirety of the HER2 negative ER positive population is addressable by our value proposition. The latest data from Optima happens to add predictive claims to the node positive population, both postmenopausal and premenopausal.”

“Yeah, so the practice of managing prostate cancer from localized disease through now metastatic disease is evolving very, very quickly, becoming far more complex than it had been.”